Ken Griffin Akero Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,200 shares of AKRO stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,200

Previous 57,800 28.72%

Holding current value

$1.26 Million

Previous $1.36 Million 12.77%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $5.26 Million - $7.19 Million	-245,216 Reduced 62.06%	149,901 $4.3 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $449,382 - $604,248	-24,543 Reduced 5.85%	395,117 $9.27 Million
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $1.16 Million - $2.04 Million	-65,365 Reduced 13.48%	419,660 $10.6 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $2.08 Million - $9.18 Million	182,438 Added 60.29%	485,025 $11.3 Million
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $959,932 - $1.22 Million	-23,305 Reduced 7.15%	302,587 $15.3 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $19.5 Million - $30.1 Million	-529,816 Reduced 61.92%	325,892 $15.2 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $22.1 Million - $29.8 Million	593,991 Added 226.96%	855,708 $32.7 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $2.83 Million - $4.63 Million	84,556 Added 47.73%	261,717 $14.3 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $797,292 - $2.67 Million	78,551 Added 79.66%	177,161 $6.03 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $86,400 - $162,108	10,800 Added 12.3%	98,610 $932,000
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $783,011 - $1.34 Million	60,371 Added 220.02%	87,810 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $107,894 - $142,483	-5,430 Reduced 16.52%	27,439 $580,000
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $469,849 - $641,413	-25,193 Reduced 43.39%	32,869 $735,000
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $2.05 Million - $2.68 Million	-82,813 Reduced 58.78%	58,062 $1.44 Million
Q1 2021 May 17, 2021	SELL	$24.04 - $34.19 $1.8 Million - $2.56 Million	-74,829 Reduced 34.69%	140,875 $4.09 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $4.4 Million - $5.23 Million	175,013 Added 430.1%	215,704 $5.57 Million
Q3 2020 Nov 16, 2020	SELL	$30.79 - $39.92 $521,089 - $675,606	-16,924 Reduced 29.37%	40,691 $1.25 Million
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $710,575 - $987,791	36,913 Added 178.31%	57,615 $1.44 Million
Q4 2019 Feb 14, 2020	SELL	$17.37 - $27.27 $43,720 - $68,638	-2,517 Reduced 10.84%	20,702 $459,000
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $392,168 - $693,783	23,219 New	23,219 $528,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.42B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account